-
公开(公告)号：WO2014099984A1
公开(公告)日：2014-06-26
申请号：PCT/US2013/075773
申请日：2013-12-17
Applicant: AMGEN INC.
Inventor： HOLDER, Jerry Ryan , SWAMINATH, Gayathri , MIRANDA, Leslie P. , ARAL, Jennifer , DOHERTY, Elizabeth M. , NIXEY, Thomas
CPC classification number: A61K47/48215 , A61K38/08 , A61K38/10 , A61K47/48415 , A61K47/60 , A61K47/6811 , C07K7/08 , C07K14/47 , C07K14/503
Abstract: The application is directed to APJ receptor agonist analogs having increased stability relative to the wild type apelin-13 and methods of using the agonist analogs. The analogs can be used, inter alia , in cardiac disorders such as heart failure.
Abstract translation: 该应用涉及相对于野生型apelin-13具有增加的稳定性的APJ受体激动剂类似物和使用激动剂类似物的方法。 类似物尤其可用于心脏病，例如心力衰竭。
-
公开(公告)号：WO2018136440A1
公开(公告)日：2018-07-26
申请号：PCT/US2018/013918
申请日：2018-01-16
Applicant: AMGEN INC.
Inventor： CHENG, Yuan , NETIROJJANAKUL, Chawita , HOLDER, Jerry Ryan , WU, Bin , FALSEY, James R. , HERBERICH, Bradley J. , SHAM, Kelvin , MIRANDA, Leslie P. , LU, Shu-Chen , VENIANT-ELLISON, Murielle M. , STANISLAUS, Shanaka , YIE, Junming , XU, Jing
IPC: A61K39/395 , C07K16/28 , A61P3/10
Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
-
公开(公告)号：WO2018237095A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/038634
申请日：2018-06-20
Applicant: AMGEN INC.
Inventor： WALKER, Kenneth W. , HOLDER, Jerry Ryan , LLOYD, David J. , LU, Shu-Chen , VENIANT-ELLISON, Murielle M. , STANISLAUS, Shanaka
Abstract: Method of treating metabolic diseases and disorders using a composition comprising a GLP-l/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.
-
公开(公告)号：WO2015191781A2
公开(公告)日：2015-12-17
申请号：PCT/US2015/035205
申请日：2015-06-10
Applicant: AMGEN INC.
Inventor： HOLDER, Jerry Ryan , SWAMINATH, Gayathri , FROHN, Michael J. , LANMAN, Brian Alan , REED, Anthony B. , MIRANDA, Leslie P. , ALLEN, John Gordon , PICKRELL, Alexander J. , SIEGMUND, Aaron C. , PENNINGTON, Lewis D. , YANG, Bryant
CPC classification number: C07K7/08 , A61K38/00 , A61K38/10 , A61K47/542 , A61K47/60 , C07K14/47 , C07K2319/30
Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
Abstract translation: 本发明提供了相对于天然apelin-13多肽具有增加的稳定性，循环半衰期和/或效力的修饰的apelin多肽。 还公开了包含修饰的apelin多肽的组合物和使用该多肽治疗心脏病症如心力衰竭的方法。
-
公开(公告)号：WO2014165277A2
公开(公告)日：2014-10-09
申请号：PCT/US2014/025062
申请日：2014-03-12
Applicant: AMGEN INC.
Inventor： MURRAY, Justin K. , HOLDER, Jerry Ryan , WANSKA, Malgorzata , TEGLEY, Christopher M. , FALSEY, James R. , DOHERTY, Elizabeth M. , MIRANDA, Leslie P. , BISWAS, Kaustav , WU, Bin , SHAM, Kelvin , LONG, Jason C.
IPC: C07K14/435
CPC classification number: C07K14/43518 , A61K38/00 , A61K38/1767 , A61K47/48284 , A61K47/48438 , A61K47/643 , A61K47/6817
Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.
Abstract translation: 公开了包含分离的多肽的物质组合物，其是外周限制的Nav1.7抑制剂。 在一些公开的实施方案中，分离的多肽是Nav1.7的抑制剂。 其它实施方案是本发明组合物和包含本发明组合物的药物组合物的共轭实施方案。 公开了编码本发明多肽和表达载体的一些实施方案的分离的核酸，以及含有它们的重组宿主细胞。 还公开了治疗或预防疼痛的方法。
-
Patent Agency Ranking
公开(公告)号：WO2007048026A2
公开(公告)日：2007-04-26
申请号：PCT/US2006/041220
申请日：2006-10-20
Applicant: AMGEN INC. , GEGG, Colin V., Jr. , MIRANDA, Leslie P. , WALKER, Kenneth W. , JOHNSON, Eileen J. , HOLDER, Jerry Ryan , WRIGHT, Marie E. , D'AMICO, Derin C.
Inventor： GEGG, Colin V., Jr. , MIRANDA, Leslie P. , WALKER, Kenneth W. , JOHNSON, Eileen J. , HOLDER, Jerry Ryan , WRIGHT, Marie E. , D'AMICO, Derin C.
CPC classification number: A61K38/225 , C07K14/57527
Abstract: Disclosed is a composition of matter that involves a CGRP peptide antagonist. A pharmaceutical composition is disclosed that comprises the composition of matter and a pharmaceutically acceptable carrier, which can be configured for administration to a patient. Also disclosed is a method of producing the composition of matter. Methods of treating, preventing or mitigating migraine, are also disclosed.
Abstract translation: 公开了涉及CGRP肽拮抗剂的物质组合物。 公开了药物组合物，其包含可配置用于施用于患者的物质组合物和药学上可接受的载体。 还公开了生产物质组合物的方法。 还公开了治疗，预防或缓解偏头痛的方法。
-
公开(公告)号：EP3155002A2
公开(公告)日：2017-04-19
申请号：EP15797720.8
申请日：2015-06-10
Applicant: Amgen Inc.
Inventor： HOLDER, Jerry Ryan , SWAMINATH, Gayathri , FROHN, Michael J. , LANMAN, Brian Alan , REED, Anthony B. , MIRANDA, Leslie P. , ALLEN, John Gordon , PICKRELL, Alexander J. , SIEGMUND, Aaron C. , PENNINGTON, Lewis D. , YANG, Bryant
Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
Abstract translation: 本发明提供相对于天然爱帕琳肽-13多肽具有增加的稳定性，循环半衰期和/或效力的修饰的爱培林多肽。 还公开了包含修饰的爱帕琳肽多肽的组合物和使用该多肽治疗心脏疾病如心力衰竭的方法。
-
公开(公告)号：EP2935311A1
公开(公告)日：2015-10-28
申请号：EP13821554.6
申请日：2013-12-17
Applicant: Amgen Inc.
Inventor： HOLDER, Jerry Ryan , SWAMINATH, Gayathri , MIRANDA, Leslie P. , ARAL, Jennifer , DOHERTY, Elizabeth M. , NIXEY, Thomas
CPC classification number: A61K47/48215 , A61K38/08 , A61K38/10 , A61K47/48415 , A61K47/60 , A61K47/6811 , C07K7/08 , C07K14/47 , C07K14/503
Abstract: The application is directed to APJ receptor agonist analogs having increased stability relative to the wild type apelin-13 and methods of using the agonist analogs. The analogs can be used, inter alia, in cardiac disorders such as heart failure.
Abstract translation: 该应用涉及具有相对于野生型apelin-13的稳定性增加的APJ受体激动剂类似物和使用激动剂类似物的方法。 类似物尤其可用于心脏病，例如心力衰竭。
-
公开(公告)号：EP4480537A2
公开(公告)日：2024-12-25
申请号：EP24198214.9
申请日：2018-01-16
Applicant: Amgen Inc.
Inventor： CHENG, Yuan , NETIROJJANAKUL, Chawita , HOLDER, Jerry Ryan , WU, Bin , FALSEY, James R. , HERBERICH, Bradley J. , SHAM, Kelvin , MIRANDA, Leslie P. , LU, Shu-Chen , VENIANT-ELLISON, Murielle M. , STANISLAUS, Shanaka , YIE, Junming , XU, Jing
IPC: A61P3/10
Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
-
公开(公告)号：EP3907237A1
公开(公告)日：2021-11-10
申请号：EP21160055.6
申请日：2013-12-17
Applicant: Amgen Inc.
Inventor： HOLDER, Jerry Ryan , SWAMINATH, Gayathri , MIRANDA, Leslie P. , ARAL, Jennifer , DOHERTY, Elizabeth M. , NIXEY, Thomas
Abstract: The application is directed to APJ receptor agonist analogs having increased stability relative to the wild type apelin-13 and methods of using the agonist analogs. The analogs can be used, inter alia, in cardiac disorders such as heart failure.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.041 seconds)
